Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Telomir Pharmaceuticals, Inc. (TELO) had Consolidated Net Income/Loss of $-5.07M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-5.07M |
|
-- |
|
-- |
|
$5.07M |
|
$-5.07M |
|
$0.00M |
|
$-5.07M |
|
$-5.07M |
|
$-5.07M |
|
$-5.07M |
|
|
Consolidated Net Income/Loss |
$-5.07M |
$-5.07M |
|
$-5.07M |
|
$-5.07M |
|
30.01M |
|
30.01M |
|
$-0.17 |
|
$-0.17 |
|
| Balance Sheet Financials | |
$0.83M |
|
-- |
|
-- |
|
$0.83M |
|
$0.35M |
|
-- |
|
-- |
|
$0.35M |
|
$0.48M |
|
$0.48M |
|
$0.48M |
|
30.51M |
|
| Cash Flow Statement Financials | |
$-1.56M |
|
-- |
|
$1.05M |
|
$1.27M |
|
$0.75M |
|
$-0.51M |
|
$6.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.38 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.56M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-1053.54% |
|
-1053.54% |
|
-611.12% |
|
-1053.54% |
|
$0.02 |
|
$-0.05 |
|
$-0.05 |
|